ArticleThe Journal of infectious diseases2021
Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A Review of Network Models for HIV Spread.Journal of acquired immune deficiency syndromes (1999) · 2025Pooled it
- PrEP reinitiation, uptake, and persistence as targets for reducing HIV incidence and racial and ethnic inequities among men who have sex with men in Boston, USA: a network modeling study.Lancet regional health. Americas · 2026Article
- Modeling the Potential Impact of Scaling Up Event-Driven PrEP Among Gay, Bisexual, and Other Men who have Sex with Men.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States.Journal of the International AIDS Society · 2026Article
- Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Acceptability and Preferences of Long-Acting Injectable Pre-Exposure Prophylaxis and Antiretroviral Therapy Among Men Who Have Sex With Men and People Who Inject Drugs in India: Insights for Future Implementation.Journal of the International AIDS Society · 2026Article
- Brief Report: Long-Acting Injectable PrEP Can Substantially Reduce HIV Incidence in Los Angeles County: A Simulation Study.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Avoiding the cost of complacency: barriers and solutions to ending the HIV epidemic in Europe.Frontiers in public health · 2026Article
- Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities.Journal of the International AIDS Society · 2026Article
- Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.Journal of general internal medicine · 2026Article
- Patient pathways to PrEP persistence: a qualitative resilience-focused journey mapping study with cisgender Black and Latino men who have sex with men and clinical PrEP staff at a federally qualified health center.Frontiers in health services · 2026Article
- Preference for Long-Acting Injectable PrEP Compared With Daily Oral PrEP Among Transgender Women in the U.S.: Findings From a Multisite Cohort.AJPM focus · 2025Article
- Exploring Willingness to Use Long-Acting Injectable PrEP Among Sexual and Gender Minoritized People Accessing Pharmacies.AIDS education and prevention : official publication of the International Society for AIDS Education · 2025Article
- Article
- HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment.Addiction science & clinical practice · 2024Article
- Marginal health care expenditures and health-related quality of life burden in patients with migraine.Journal of managed care & specialty pharmacy · 2024Article
- Brief Report: Interest in Long-acting Injectable PrEP Among Transgender Women in Eastern and Southern United States.Journal of acquired immune deficiency syndromes (1999) · 2024Article
- Long-acting Injectable PrEP Interest and General PrEP Awareness among People who Inject Drugs in the San Diego-Tijuana Border Metroplex.AIDS and behavior · 2024Article
- Modeling the impact of changing sexual behaviors with opposite-sex partners and STI testing among women and men ages 15-44 on STI diagnosis rates in the United States 2012-2019.Infectious Disease Modelling · 2023Article
- Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States.BMC public health · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundLong-acting injectable (LAI) human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) is reportedly efficacious, although full trial results have not been published. We used a dynamic network model of HIV transmission among men who have sex with men to assess the population impact of LAI-PrEP when available concurrently with daily-oral (DO) PrEP.
methodsThe reference model represents the current HIV epidemiology and DO-PrEP coverage (15% among those with behavioral indications for PrEP) among men who have sex with men in the southeastern United States. Primary analyses investigated varied PrEP uptake and proportion selecting LAI-PrEP. Secondary analyses evaluated uncertainty in pharmacokinetic efficacy and LAI-PrEP persistence relative to DO-PrEP.
resultsCompared with the reference scenario, if 50% chose LAI-PrEP, 4.3% (95% simulation interval, -7.3% to 14.5%) of infections would be averted over 10 years. The impact of LAI-PrEP is slightly greater than that of the DO-PrEP-only regimen, based on assumptions of higher adherence and partial protection after discontinuation. If the total PrEP initiation rate doubled, 17.1% (95% simulation interval, 6.7%-26.4%) of infections would be averted. The highest population-level impact occurred when LAI-PrEP uptake and persistence improved.
conclusionsIf LAI-PrEP replaces DO-PrEP, its availability will modestly improve the population impact. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage, or if persistence is greater for LAI-PrEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.